- info@inquismedical.com
- 888-526-7738
- 1530 O'Brien Drive, Suite A Menlo Park, CA 94025
Vahid Saadat is a serial medical device entrepreneur with over 25 years of experience developing medical devices. Prior to Inquis Medical, Vahid was the CEO of Arrinex, the maker of ClariFix, an innovative product that provides long-term relief to chronic rhinitis sufferers. Vahid also started an electrophysiology company named Voyage Medical Inc., where he developed IRIS™, the first direct endocardial visualization system. Vahid’s other startups include Baxano, a spinal stenosis treatment company, USGI, which specializes in incisionless surgery technology, and AngioTrax, an interventional cardiology company. Prior to AngioTrax Vahid spent several years on executive leadership positions of different medtech companies. Vahid holds a BS degree in Electrical Engineering and a MS degree in Biomedical Engineering from the University of Texas at Austin.
As an entrepreneur for most of her career, Mojgan has many years of hands-on start up experience. Mojgan has been a partner at Nidus Medical, LLC, a medical device incubator and angel investment entity, and has led the launch of Nidus Medical spinoff companies. Prior to Inquis Medical launch, she co-founded Arrinex, Inc., and served as its President. Arrinex Inc., now part of Stryker ENT, changed the treatment paradigm for patients with chronic rhinitis. Prior to Arrinex, Mojgan co-founded the eHealth company CongniTX, utilizing Heads Up Displays (HUDs) to help individuals with cognitive disorders. Prior to CogniTX, Mojgan led the launch of Seris Medical, a China-based company developing a device for passive drainage of ascites fluid in patients with late stage liver disease. Mojgan holds two Bachelor of Science degrees in Biology and Computer Science.
Dan has over 25 years of experience in finance and accounting with private and public companies in both a full-time and consulting capacity. Dan manages his professional services practice that specializes in executive financial services to healthcare companies, including mergers and acquisitions across a broad range of specialties. Most recently, Dan served as the Chief Financial Officer and Treasurer of Lucira Health, Inc., a medical diagnostics company, bringing it to the public market. Previously, he served as Vice President, Finance for Avinger Inc. that specializes in peripheral atherectomy, supporting its public offering (NASDAQ: AVGR); Vice President of Finance for ApniCure, Inc. that focuses on the treatment of sleep apnea; Chief Financial Officer for Avantis Medical Systems, Inc. that specializes on colonoscopy visualization technology; and Sr. Director of Finance at FoxHollow Technologies Inc, supporting its public offering. Dan began his career in the assurance and business advisory practice of PricewaterhouseCoopers LLP. Dan holds B.S. degrees in both Accounting and Finance from California State University, Long Beach.
Jason has over 20 years of experience developing medical devices, therapies and IP primarily focusing in the ENT, cardiovascular and vascular specialties. Most recently, he served as VP of R&D for Arrinex (acquired by Stryker). Prior to Arrinex, Jason was the Chief Development Officer at SinuSys developing an osmotic sinus dilation technology. Prior to SinuSys, Jason assisted in the development of the Nellix EVAR system (acquired by Endologix). Prior to Nellix, Jason held multiple roles in research & development at Guidant Corp. (acquired by Abbott) and AcelRx Pharmaceuticals, Inc. Jason has co-authored over 30 Patents and Patent Applications in the laser and medical device fields. Jason holds a BS in Mechanical Engineering from the Rose-Hulman Institute of Technology and post graduate certifications from Stanford University.
Matt has over 20 years of experience as a commercial leader in the healthcare and medical device industries. Throughout his career, Matt has accumulated vast expertise in leading sales organizations, developing and executing commercial strategies, and introducing new products into the healthcare market. Most recently, he served as the Vice President/General Manager of Becton Dickinson (BD) Peripheral Intervention where he led the US sales team in strategies to combat disease states of peripheral vascular, venous, end stage kidney, cancer, and women’s health. Matt holds a Bachelor’s degree in finance and management information systems from the University of Wisconsin-Eau Claire. After college, he began his career in the healthcare industry as a sales representative for a large pharmaceutical company. He made the move to Bard Peripheral Vascular (later purchased by BD) to sell medical devices in 2009. In his various roles with the industry giant, Matt was instrumental in launching Lutonix (Peripheral Drug Coated balloon), Venovo (Venous stent), and Rotarex (Arterial Atherectomy & Thrombectomy).
Mike has over 20 years of R&D experience in the medical device industry focused on hardware and software designs, algorithms and complex development projects mainly in the cardiovascular space. After earning a B.S. in Mathematics at Northeastern and an M.S. in Electrical Engineering with a concentration in medical devices and medical imaging at Stanford University, he worked as an R&D engineer at Boston Scientific in the electrophysiology division. He then joined EBR Systems designing electronics, managing projects and developing algorithms. Next, at Sonitus Technologies, Mike ran the R&D group including hardware, software and mechanical engineers, and developed from concept through commercial release a two-way communication system worn inside the mouth. Most recently, Mike served as the Systems Engineering Manager at Farapulse managing internal hardware and software engineers as well as an external consulting group to develop a novel Pulsed Electric Field system to treat atrial fibrillation.
Zachary has worked in the medical device industry for nearly 30 years focused on cardiovascular devices. He has worked extensively in the quality and regulatory space for both start-ups and large corporations. Prior to joining Inquis, Zachary served as the Vice President of QA/RA for both LimFlow and Claret Medical where he helped bring Transcatheter Arterialization of Deep Veins (TADV) and Cerebral Embolic Protection products to the US market. Zachary has spent is career working on innovative therapies to treat arterial and peripheral disease, hypertension, embolic protection, and chronic limb threatening ischemia. He looks forward to working at Inquis and helping patients suffering from thromboembolic disease. Zachary is a graduate of Sonoma State University with a Bachelor’s degree in Psychology.
John has extensive experience developing and executing strategic marketing plans for both commercial and pre-commercial stage companies. Most recently, he was the Director of Global Marketing for LimFlow SA (acquired by Inari Medical for $415M), where he led the market introduction of the novel TADV (Transcatheter Arterialization of the Deep Veins) therapy to prevent amputation in patients with chronic limb-threatening ischemia (CTLI). With deep expertise in product launch planning and execution, he has successfully managed and scaled multiple medical device product lines, addressing significant unmet needs in the healthcare sector. John holds a Master’s of Business and Science degree from the Keck Graduate Institute and a Bachelor’s degree in Biomedical Engineering from the University of Southern California. His unique blend of technical and business expertise allows him to effectively drive product development in collaboration with R&D teams while delivering strong marketing results.
Richard Childs is a technical design leader with deep expertise in catheter design and cardiovascular procedure development. He began his career advancing structural heart repair at Abbott, contributing to the development of novel transcatheter therapies within the company’s Structural Heart division. Richard then took on pivotal R&D leadership roles at Silara Medtech and MVRx, both specialized startups focused on developing next generation transcatheter valve therapies and other innovative interventions for structural heart disease.
With proven experience guiding innovative concepts from initial prototype through to full product commercialization, Richard excels at leading cross-functional teams to solve complex technical challenges and deliver transformative medical devices that address critical patient needs. He is known for his ability to drive technical excellence while fostering collaboration across engineering, clinical, and commercial functions.
Richard holds a Bachelor of Engineering in Mechanical Engineering from Munster Technological University in Ireland
Catherine has over 14 years of experience leading clinical trials for endovascular medical devices at early-stage companies. At Vesper Medical (acquired by Philips), she guided the design and execution of a pivotal trial for a venous stent system, resulting in PMA approval for the iliofemoral indication. Previously, at Intact Vascular (also acquired by Philips), she managed trial operations and data analysis for trials that led to PMA and CE-mark approvals for novel nitinol scaffolds, including the first in the US for below-the-knee arterial use. Earlier in her career, Catherine ran clinical and regulatory operations for Flexible Stenting Solutions, supporting European and pivotal US trial efforts until its acquisition by Cordis Corporation in 2013. She holds a Master’s in Clinical Trial Sciences from the University of Medicine and Dentistry of NJ and a Bachelor’s in Psychology from Rutgers University. Her extensive experience in MedTech enables strategic and effective trial design, execution, and cross-functional collaboration, driving meaningful outcomes that empower physicians with innovative solutions to improve patient lives.
Dr. Shishehbor is an interventional cardiologist with expertise in vascular medicine and minimally invasive procedures to treat coronary, carotid and abdominal aortic aneurysms, peripheral artery disease (PVD) and venous disease. Currently, he serves as the President, University Hospitals Harrington Heart & Vascular Institute, as the co-chair of the PVD Council for Society for Cardiovascular Angiography and Interventions (SCAI) and as a member of PVD council for the American College of Cardiology (ACC). Dr. Shishehbor is a National Institutes of Health scholar, winner of the Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award and the VIVA/LINC Young Leader’s Award in Vascular (2009). He was the writing member ACC/AHA/SCAI/SVS/SIR Guidelines for Lower Extremity Peripheral Artery Disease (2017, 2021) and a member of the Appropriate Use Criteria committee for renal and peripheral intervention for SCAI (2017). He served as the chair of the Masters’ Approach to Critical Limb Ischemia Symposium (2016) and co-founded the not-for-profit Cardiovascular Innovations Foundation.
Jim Heslin has been recognized as a leading intellectual property attorney and held an AV-Preeminent rating from Martindale Hubbell for over 20 years. After earning a BS in Chemical Engineering from UC Santa Barbara and a JD from UC Berkeley, he went on to found and lead the medical device technology patent group at Townsend and Townsend and Crew (now Kilpatrick Townsend) and served as Vice President and General Counsel for Align Technology. Prior to Inquis Medical, he was a partner at Wilson Sonsini where he focused on helping medical device companies protect and enforce their domestic and international intellectual property rights, as well as advising venture capitalists who invest in medical technology companies.
David A. Lamond joined Inquis Medical’s Board of Directors in December 2019 and serves as its Chairperson. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC. Mr. Lamond also is currently the chairman of the board of directors of Quince Therapeutics and a member of the board of directors of Applied Molecular Transport (AMTI). He previously served on the board of Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019, and on the board of Lucira Health Inc, a molecular diagnostics company. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a BA in History from Duke University and a JD from Duke Law School.
Bruce Shook is a seasoned medical technology entrepreneur with over 35 years of industry experience, including multiple early-stage ventures focused in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. In 2016, Mr. Shook formed Vesper Medical as a spinout of Intact Vascular, where he served as President & CEO. Previously, Mr. Shook served as co-founder, Director, President and CEO of both Neuronetics and Neuron Therapeutics; President at Abiomed, where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook has served on several corporate boards, including Devoro Medical (acquired by Boston Scientific), Surgiquest (acquired by Conmed), Respicardia (acquired by Zoll) and CoTherix (acquired by Actelion). Currently, he serves as the Board Chair for Life Sciences PA and the Penn State Research Foundation. Mr. Shook obtained advanced degrees in Biomedical Engineering from Columbia University and Business Administration from the MIT Sloan School of Management. He also holds a BS degree in Chemical Engineering from Penn State University.
Andrew D. Goldberg, MD is a Portfolio Manager at Marshall Wace and helps lead the XO Healthcare Innovation fund, which makes late-stage private and public investments. Before this he was a Partner at Palo Alto-based Vivo Capital, where he focused on biotech, pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in the Silicon Valley office in their pharmaceutical and medical products practice. Dr. Goldberg is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona and the Washington Township Medical Foundation.
Dr. Jun Li is an interventional cardiologist and endovascular specialist at University Hospitals Harrington Heart & Vascular Institute. Currently she serves as Co-Director of the Vascular Center and Co-Director of the Pulmonary Embolism Response Team (PERT) Program. Dr. Li is also an Assistant Professor at Case Western Reserve University School of Medicine. In addition to her clinical practice, Dr. Li has been an invited speaker at more than 30 professional conferences and has authored nearly 50 peer-reviewed publications and book chapters on topics related to heart and vascular disease interventions. Dr. Li is an active member of multiple nationally distinguished organizations including the American College of Cardiology, American College of Physicians, Transcatheter Cardiovascular Therapeutics and American Society of Echocardiography. She also serves on the Peripheral Vascular Disease Leadership Committee of the American Heart Association, and the Vascular Disease Council of the Society for Cardiovascular Angiography & Interventions (SCAI).
Dr. Saher S. Sabri is the Chief of Interventional Radiology at MedStar Health and Division Chief of Interventional Radiology at MedStar Georgetown University Hospital. Dr. Sabri is also a Professor of Radiology at MedStar Georgetown University Hospital. He was previously Associate Professor of Radiology and Surgery, Vice Chair of Education, and Residency Program Director for the Department of Radiology and Medical Imaging at the University of Virginia Medical School. He is a fellow of the Society of Interventional Radiology, holds the American Board of Radiology Certificate of Added Qualifications (CAQ) in vascular and interventional radiology and is a board examiner for the American Board of Radiology. Dr. Sabri specializes in minimally invasive, image-guided therapy for the treatment of a wide variety of conditions, such as peripheral vascular disease, dialysis access management, aortic aneurysm, portal hypertension, uterine fibroids and local/regional therapy for liver, kidney and lung cancer.
